News | February 18, 2008

Bioabsorable Stent May Reduce MACE Related to DES

February 19, 2008 – A novel, fully bioabsorbable salicylate-based stent offers the potential to reduce adverse events associated with current drug-eluting stents (DES) and could be very beneficial to patients with coronary heart disease, according to a presentation at the Cardiovascular Revascularization Therapies 2008 (CRT) symposium.

Refat Jabara, M.D., of the scientific team from Atlanta-based Saint Joseph’s Translational Research Institute (SJTRI), presented his abstract "Novel Anti-Inflammatory Salicylate-Based Bioabsorbable Drug-Eluting Polymeric Coating" from the podium during oral presentations of the 'Best Ten Abstracts' category. Dr. Jabara received Top Five Abstract Award honors for the work from the course chairman, Ron Waksman, M.D.

“At SJTRI, we are in the process of evaluating several variations of the next generation of intravascular stents. As demonstrated in this study, the technology of a fully bioabsorbable stent platform could lead to dramatic advances in the clinical treatment of patients with coronary heart disease. I am fortunate to be able to contribute to the assessment of these devices and the impact that they may have on the health and welfare of patients around the world,” said Dr. Jabara.

For more information: www.crtonline.org

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation| March 31, 2017
Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was...
Sponsored Content | Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
Overlay Init